.jpg)
Listen: Aduhelm’s latest twist, how Covid variants are shaping the summer, & a digital health boom
How worrying is the Delta variant? Is there a digital health bubble? And what is going on at the FDA?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss the latest twists following the FDA’s widely condemned decision to approve Aduhelm, Biogen’s treatment for Alzheimer’s disease. Then, our STAT colleague Helen Branswell joins us to talk about whether viral variants are going to stymie the U.S.’s summer reopening. Finally, STAT’s Mario Aguilar calls in to break down the record-setting sums going into digital health companies in 2021.
